Clinical Trials Search Results
Results 1-10 of 357 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Keywords/Phrases: | "colorectal cancer" |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic HER2 / Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 651 locations
Age: 18 years and over
Gender: Male or Female
Location: 651 locations
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient with Locally Advanced Rectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 624 locations
Age: 18 years and over
Gender: Male or Female
Location: 624 locations
Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 806 locations
Age: 18 years and over
Gender: Male or Female
Location: 806 locations
Combination Chemotherapy, Bevacizumab, and / or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 305 locations
Age: 18 years and over
Gender: Male or Female
Location: 305 locations
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 28 locations
Age: 18 years and over
Gender: Male or Female
Location: 28 locations
Phase 1 / 2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Active
Age: 12 years and over
Gender: Male or Female
Location: 27 locations
Age: 12 years and over
Gender: Male or Female
Location: 27 locations
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Age: 18 years and over
Gender: Female
Location: 26 locations
Age: 18 years and over
Gender: Female
Location: 26 locations
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Age: 18 years and over
Gender: Male or Female
Location: 24 locations